Altimmune, Inc. (NASDAQ:ALT – Free Report) – Equities researchers at HC Wainwright issued their FY2029 EPS estimates for Altimmune in a research note issued on Wednesday, January 22nd. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of $1.30 per share for the year. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share.
ALT has been the topic of several other research reports. UBS Group assumed coverage on shares of Altimmune in a report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 target price on the stock. Stifel Nicolaus began coverage on shares of Altimmune in a research note on Wednesday, January 8th. They issued a “buy” rating and a $18.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Altimmune presently has an average rating of “Buy” and an average target price of $20.83.
Altimmune Stock Performance
Shares of NASDAQ:ALT opened at $7.00 on Monday. The firm has a market cap of $497.84 million, a PE ratio of -4.52 and a beta of 0.22. Altimmune has a 52 week low of $5.28 and a 52 week high of $14.84. The firm’s fifty day moving average is $7.88 and its 200-day moving average is $7.20.
Altimmune (NASDAQ:ALT – Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. The company had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter last year, the firm posted ($0.39) EPS.
Hedge Funds Weigh In On Altimmune
A number of institutional investors have recently made changes to their positions in ALT. Dimensional Fund Advisors LP grew its holdings in shares of Altimmune by 142.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after purchasing an additional 335,444 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Altimmune during the 2nd quarter valued at about $96,000. The Manufacturers Life Insurance Company boosted its stake in Altimmune by 30.7% during the second quarter. The Manufacturers Life Insurance Company now owns 26,973 shares of the company’s stock worth $179,000 after acquiring an additional 6,339 shares in the last quarter. B. Riley Wealth Advisors Inc. bought a new stake in Altimmune during the second quarter worth about $138,000. Finally, PVG Asset Management Corp bought a new position in shares of Altimmune in the second quarter worth approximately $154,000. Institutional investors own 78.05% of the company’s stock.
Altimmune Company Profile
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
Further Reading
- Five stocks we like better than Altimmune
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Sizing Up a New Opportunity for NVIDIA Investors
- Investing in Travel Stocks Benefits
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.